HUTCHMED (China) Ltd (HCM)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
218.00p
Buy
229.00p
-3.00p (-1.35%)
Prices updated at 02 Apr 2026, 16:35 BST
| Prices minimum 15 mins delay
Prices in GBX
Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform aimed at discovering and developing therapeutics in oncology and autoimmune diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Dan Eldar
CEO
Mr. Johnny Cheng Chig FUNG
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
1,811
Head office
2 Queen's Road Central
Hong Kong
Hong Kong
Key personnel
Owner name | Salary |
|---|---|
Professor Shu Kam Tony Mok Non-Executive Director, Senior Independent Director | - |
Ms. Edith Shih Non-Executive Director, Company Secretary | - |
Mr. Dan Eldar Non-Executive Director, Chairman | - |
Dr. Renu Bhatia Non-Executive Director | - |
Mr. Johnny Cheng Chig FUNG Executive Director, Acting Chief Executive Officer and Chief Financial Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| China Universal Asset Mgmt Co.Ltd | 21,195,000 |
| China Universal CNI HK Eq Cn Innv Dg ETF | 20,102,000 |
| GF Fund Mgmt Co.,Ltd | 15,919,900 |
| GF CSI Hong Kong Brand Nm Drug ETF(QDII) | 15,885,000 |
| M&G Investment Management Limited | 10,210,100 |
Director dealings
Date | Action |
|---|---|
| 13 Mar 2026 | Transfer in |
| 10 Mar 2026 | Transfer in |
| 10 Mar 2026 | Transfer in |
| 20 Oct 2025 | Transfer in |
| 20 Oct 2025 | Transfer in |
Please note that past performance is not a reliable indicator of future returns.